chartexchange

Cocrystal Pharma Posts Wider Q3 Loss, Led By Norovirus Challenge Study Costs

RTTNews | Nov 16, 2026 2:23 AM EST


(RTTNews) - Cocrystal Pharma, Inc. (COCP), a clinical stage biotechnology firm, on Sunday reported a wider loss in its third quarter, driven by higher clinical trial and related expenses mainly associated with the Phase 1b norovirus challenge study of norovirus candidate CDI-988.

Read original article